Floatz logo

STAPULDENCEL

Peritoneal Carcinoma

SOTIO a.s.Cell therapyPhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Peritoneal Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
CanariaBio Inc.
Phase 3BB
Eloxatin
University of Utah
Phase 2B
Interferon Gamma-1B
InterMune
Phase 3B
Gefetinib
Massachusetts General Hospital
Phase 2B
Arimidex
Massachusetts General Hospital
Phase 2B

View all 18 →

Same molecule, other indications

STAPULDENCEL is also rated in:

ovarian carcinomaDormant
B
Indicative ·
62 / 100
View asset →
metastatic prostate carcinomaDormant
B
Indicative ·
59 / 100
View asset →
prostate cancerDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →